NY-ESO-1-redirected T Cells in Patients With Advanced Melanoma and Sarcoma

Prior treatment

• Patients with symptomatic and/or untreated brain metastases, as well as leptomeningeal carcinomatosis. Patients with definitively treated brain metastases will be considered for enrolment after agreement with the Principal Investigator, as long as lesions are stable, there are no new brain lesions, and the patient does not require chronic corticosteroid treatment.
• History of recent myocardial infarction, or unstable angina, within six months prior to enrolment
• Patients with prior allogeneic stem cell transplantation or organ transplantation
• Active severe systemic infections within 2 weeks prior to apheresis
• Patient requiring regular systemic immunosuppressive therapy. All immunosuppressive medications including but not limited to steroids, mycophenolate mofetil, azathioprine, methotrexate, thalidomide, and anti-Tumor Necrosis Factor-alpha (TNF-alpha) agents must have been discontinued at least 2 weeks before apheresis .

Other illness

• Patients with an active second malignancy
• History of idiopathic pulmonary fibrosis or evidence of active pneumonitis (any origin). History of radiation pneumonitis in the radiation field (fibrosis) is allowed.
• History of severe immediate hypersensitivity reaction to any of the agents/ excipients of the study products.
• Any serious underlying medical condition that could interfere with study medication and potential adverse events.

Other

• Women who are pregnant or breastfeeding because of the potentially dangerous effects of the treatment on the fetus or infant.
• Subjects, for whom there are concerns that they will not reliably comply with the requirements for contraception, should not be enrolled into the study.

• 1\) Patients with histologically confirmed advanced or metastatic cutaneous melanoma or any type of sarcoma.
• Patients with sarcoma, who have received at least one line of standard therapy (if available) and failed to respond, progressed or were intolerant to that therapy, will be eligible. If the participant refuses or is, in the opinion of the investigator, ineligible for these treatments, the reason must be documented in the medical record.
• Patients with metastatic melanoma:
  • Without proto-oncogene B-Raf (BRAF) mutation who have received at least one line of standard therapy and failed to respond, progressed or were intolerant to that therapy, will be eligible. If the participant refuses or is, in the opinion of the investigator, ineligible for these treatments, the reason must be documented in the medical record.
  • With BRAF mutation who have received at least two lines of standard therapy and failed to respond, progressed or were intolerant to that therapy, will be eligible. If the participant refuses or is, in the opinion of the investigator, ineligible for these treatments, the reason must be documented in the medical record.
• Patient must have immunohistochemically documented NY-ESO-1 expression, defined as ≥ 1+ expression on either archival or fresh tumor tissue by immunohistochemistry, in ≥50% of the sampled tumor tissue AND HLA-A\*0201 and/or HLA-A\*0205 positive, as identified by high-resolution genomic deoxyribonucleic acid (DNA) typing of the HLA-A locus.
• Age ≥ 18 years
• Able to undergo apheresis
• At least one lesion accessible to biopsy for translational research (TR) at D30, without putting the patient at unusual risk.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
• Life expectancy of greater than 12 weeks.
• Radiologically measurable disease (as per RECIST v1.1).
• Adequate organ function